BioDtech, Inc. Issued New United States Patent
News Feb 20, 2013
The patent, entitled “Enhancing Endotoxin Detection,” covers the company’s EndoPrepTM and ESPTM technologies for the use of accurate endotoxin detection in biopharmaceuticals and human plasma, respectively.
This is the second patent issued to BioDtech for the protection of their intellectual property designed to detect Gram-negative bacteria in a sample, then remove and neutralize endotoxins, depending on their specific requirements.
“The technology covered by this patent has broad applications that enable better safety and efficacy for biotherapeutics and monitoring of inflammation based diseases,” stated Dr. Michael Pepe PhD, President and Chief Executive Officer of BioDtech. “The company is currently pursuing the potential use of this technology for the quality control and production of biotherapeutics as well as diagnostic monitoring of gastrointestinal diseases and Gram-negative bacterial infections,” added Pepe.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Could Intermittent Fasting Diets Do Us Harm?News
Fasting every other day to lose weight impairs the action of sugar-regulating hormone, insulin, which may increase diabetes risk, according to recent data. These findings suggest that fasting-based diets may be associated with long-term health risks and careful consideration should be made before starting such weight loss programmes.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018